START operates the largest, global, 24-hour Phase I medical oncology program, putting nearly 700 patients worldwide per year on Phase I trials.  With five Phase I centers in four cities on three continents, including Madrid, Shanghai, San Antonio and Grand Rapids, START's mission is to accelerate the development of new anticancer drugs for the purpose of improving the quality of life and survival for patients with cancer.